Targeting Ferroptosis Vulnerability in Synovial Sarcoma: Is It All About ME1?

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Understanding metabolic dependencies and their therapeutic vulnerabilities is key to precision oncology. Malic enzyme 1 (ME1) is frequently overexpressed in cancers with protumorigenic effects. In contrast, consistent loss of ME1 expression in synovial sarcoma compared with other sarcomas indicates a unique ferroptosis liability for precision therapy in this form of cancer. See related article by Brashears et al., p. 3573.

Keyphrases

cell death
papillary thyroid
poor prognosis
climate change
magnetic resonance
palliative care
squamous cell
high grade
cancer therapy
binding protein
magnetic resonance imaging
squamous cell carcinoma
computed tomography
bone marrow
mesenchymal stem cells